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Conclusions: PTDM is associated with an unfavorable car-Patient survival after renal transplantation: IV. Impact of post-
diovascular risk profile that precedes the development of hy-transplant diabetes.
perglycemia. PTDM is an independent predictor of reducedBackground. The development of de novo diabetes mellitus
survival in renal allograft recipients.is a serious complication of kidney transplantation. This study
examined the cardiovascular risk profile of patients with post-
transplant diabetes (PTDM) and assessed the impact of PTDM
on patient survival. Over the last three decades considerable improve-Methods. This analysis included 1811 adult, renal allograft
ments have been made in the survival of renal allograftsrecipients, transplanted in a single institution between 1983
[1] and of their recipients [2]. Still, compared to theand 1998. Patient survival was analyzed by univariable and
multivariable Cox regression considering PTDM as a time de- general population, the survival of recipients of kidney
pendent variable. transplants is significantly reduced [3]. This observation
Results. After a follow-up period of 8.3  4.5 years, 293 may not be unexpected because patients with kidneypatients (20%) developed PTDM, 14% lost their graft, and
disease, when they reach the final stages of the disease,20% died. Compared to patients without DM (NoDM, N 
already have an unfavorable cardiovascular risk profile1186) patients with PTDM were significantly older (40  14
vs. 48  12 years, P  0.001), heavier (76  23 vs. 86  25 kg, [4]. Recent studies showed that the cardiovascular risk
P  0.001), and included more African Americans (18 vs. factors that are relevant to the general public are also
28%, P  0.001). In addition, the incidence of PTDM was relevant to patients with kidney transplants [5]. In previ-significantly higher in patients who were transplanted after
ous studies we initiated a systematic evaluation of vari-1995 than prior to that year. In contrast, there were no signifi-
ables that correlate with the survival of kidney transplantcant differences between PTDM and patients who had DM
before the transplant (DM; N  332). Compared to NoDM, recipients. Those studies led us first to the demonstration
patients with PTDM had significantly higher total serum cho- that dialysis prior to transplantation has a negative im-
lesterol and triglycerides (TG), higher systolic blood pressure pact on patient survival after transplantation [6] and also
and higher pulse pressure throughout the post-transplant pe-
that smoking has a profound negative impact on theriod. Of interest, all of these abnormalities preceded the devel-
survival of transplanted patients [7]. Our more recentopment of PTDM. Hypertriglyceridemia was particularly pro-
studies reported on variables that predispose patients tonounced in PTDM and elevated TG levels correlated with the
subsequent development of PTDM, independent of other risk the development of post-transplant diabetes (PTDM)
factors (P  0.001 by multivariate Cox). Compared to NoDM and found that the incidence of PTDM has increased
(16% mortality) a significantly higher percent of DM (31%, sharply since 1995 [8]. Our current follow-up study as-P  0.001) and PTDM (22%, P  0.005) patients died. By
sessed the possible impact of PTDM on cardiovascularCox regression, PTDM correlated with reduced patient survival
risk and on patient survival after transplantation.(hazard ratio  1.80, CI 1.35 to 2.41, P  0.001), and that
relationship was independent of other correlates of reduced Post-transplant diabetes mellitus is thought to be the
survival that included: increasing age; transplant year; reduced consequence of the development of insulin resistance
serum albumin; and male sex. after transplantation [reviewed in 9, 10]. It is also possi-
ble, and perhaps more likely, that patients who develop
PTDM have insulin resistance prior to the transplantKey words: transplantation, kidney, diabetes, survival, cardiovascular
risk. and that this condition is aggravated by the immunosup-
pressive medications used after transplantation, amongReceived for publication July 24, 2001
other factors. This postulate is supported by the observa-and in revised form April 16, 2002
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Table 1. Characteristics of the patient population plays the characteristics of the patient population. De-
tails related to the development of PTDM were reportedPatient characteristic All NoDM DM PTDM
in a previous publication [8].Number of patients 1811 1186 332 293
Age years 42.914 4014 47.512a 4812a All patients received induction immunosuppression
Gender % males 59% 58% 60% 63% during the first few days after receiving the allograft.
Race % African American 21% 18.3% 24%b 28%b
The induction agent has evolved over the years fromWeight at transplant kg 78.825 75.623 8430a 8625a
BMIc 277.5 25.96.5 299.6a 297a Minnesota ALG, to monoclonal antilymphocyte anti-
bodies (OKT3; Ortho Biotech, Raritan, NJ, USA) and ina P  0.001 by ANOVA compared to NoDM
b P  .001 by Chi square compared to NoDM the most recent past to monoclonal anti-CD25 antibodies
c BMI, body mass index  weight (kg)/height (m)2
(Basilxilimab, Simulect; Novartis, Basle, Switzerland).
Initiation of cyclosporine treatment post-transplant was
delayed until the serum creatinine was 2.5 mg /dL.
In mid 1995 all patients were started on cyclosporinedevelops within the first few weeks after transplantation
[8–10]. If indeed patients with PTDM had insulin resis- microemulsion (Neoral) rather than Sandimmune. Fur-
thermore, most patients who were on Sandimmune priortance for a period of time prior to the development
of DM, then we need to consider that the accelerated to that time were switched to Neoral. Prior to 1995 most
patients received azathioprine (Imuran) in addition todevelopment of cardiovascular disease likely started at
the time of initiation of insulin resistance, prior to the cyclosporine. However, since 1995 all patients received
mycophenolate mofetil (CellCept) instead of azathio-development of hyperglycemia, because insulin resis-
tance itself is associated with an increased cardiovascular prine as part of a triple immunosuppression protocol
that also included Neoral and prednisone. None of therisk [11].
Insulin resistance is associated with complex metabolic patients included in this study were treated with FK506
(Prograf) or with sirolimus (Rapamycin).and hemodynamic abnormalities, including [11, 12] trun-
cal obesity; hypertension; dyslipidemia; elevated proco- Clinical data were obtained mainly from an electronic
database that contains all of the clinical and laboratoryagulant factors [13]; and elevated insulin levels. Several
factors may cause—or worsen—insulin resistance in re- information in our patients. In the majority of patients,
only the levels of total serum cholesterol and triglycer-nal allograft recipients, including: (1) renal insufficiency
[14, 15]; (2) the effects of corticosteroids and calcineurin ides (TG) were obtained routinely. Thus, data on low-
density lipoprotein (LDL) and high-density lipoproteininhibitors [reviewed in 9, 16]; and (3) the frequent devel-
opment of obesity after transplantation [17]. In this study (HDL) cholesterol were not analyzed in this study. Se-
rum albumin values were analyzed as the average serumwe assessed several of the features of the insulin resis-
tance syndrome in renal transplant recipients. concentration from months 6 to 18 post-transplant. Blood
pressures (BP) were measured by the patient at home
and reported to the post-transplant office. BP determina-
METHODS
tions made during outpatient clinic visits were also in-
Patient population cluded in the analysis. Mean arterial pressure (MAP)
was calculated as [(systolic BP  diastolic BP)/3)  dia-The study population included 1811 patients who re-
ceived their first kidney transplants at The Ohio State stolic BP]. Pulse pressure (PP) was calculated as systolic
BP  diastolic BP.University between 1983 and December 1997, and who
maintained graft function for at least six months post-
Statistical analysistransplant. The mean follow-up for the population was
8.3  4.5 years. These patients were subdivided into Data in the manuscript are expressed as means 
standard deviation of the mean unless indicated other-three groups: (1) patients without diabetes before and
after the transplant (NoDM, N 1186, 66%); (2) patients wise. Proportions were compared by Chi square analysis.
Mean values in two groups were compared by the Stu-who had diabetes prior to the transplant (DM, N  332,
18%); and (3) patients who developed de novo DM dent t test or by a non-parametric test if the data were
not normally distributed. Mean values in more than twoafter the transplant (PTDM, N 293; 20%). PTDM was
diagnosed when transplanted patients who previously groups were compared by analysis of variance (ANOVA)
or by the Mann-Whitney test if the data were not nor-were not diabetic required treatment of hyperglycemia
with either oral hypoglycemic agents and/or insulin. One mally distributed. Patient survival was analyzed by both
univariate and multivariate Cox regression and displayedhundred and twenty-eight patients met these criteria but
were not included in the PTDM group, because a review in Kaplan-Meier plots. Patient survival was censored at
the time of graft loss. The correlation between PTDMof these charts revealed that these patients were hyper-
glycemic even at the time of transplantation although and patient survival was analyzed by Cox regression
where PTDM was considered a time dependent variable,they were not taking hypoglycemic drugs. Table 1 dis-
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because this complication started at different times fol-
lowing the transplant. To assure that the Cox models
were correctly interpreted, the assumption of propor-
tional hazards was formally tested.
RESULTS
Demographic characteristics of the patient population
Table 1 displays the overall characteristics of the pa-
tient population and the characteristics of each of the
patient groups. As can be seen, and as shown previously
[8], compared to the NoDM group, patients who devel-
oped PTDM were significantly older, significantly heav-
ier, and included a significantly higher percent of recipi-
ents of African American race. In contrast, there were
no significant differences between PTDM and DM pa-
tients in any of these characteristics (Table 1). As shown
previously the incidence of PTDM also correlated with
the year of transplant. Thus, PTDM developed more
frequently in patients transplanted since 1995 than be-
fore that year [8]. Additional comparisons between these
patient groups have been reported previously [8].
After a period of follow-up of 8.3  4.5 years 20% of
the patients died and 14% lost their grafts for reasons
other than patient death. Throughout the post-transplant
period 293 out of 1479 patients who were not diabetic
before the transplant developed PTDM (20%).
Dyslipidemia
Figure 1 displays average yearly total serum choles-
terol and serum TG concentrations post-transplant in
Fig. 1. Evolution of serum lipids concentrations the first six years afterNoDM, DM and PTDM patient groups. It should be kidney transplantation. (A) Total serum cholesterol levels (mean 
noted that these data include only values obtained from SEM) in the following groups of patients: no diabetes (NoDM;  );
with diabetes (DM; . . .); post-transplant diabetes (PTDM;  ).patients who were followed for the entire period of time
(B) Serum triglyceride (TG) levels (mean  SEM) in the same groupsshown in the figure, that is, six years. As can be seen in
of patients.Figure 1A, the concentration of total serum cholesterol
increased significantly during the first year post-trans-
plant in all groups of patients. Thereafter, serum choles-
terol levels declined progressively in all patient groups. ceded the development of diabetes. This is shown in Fig-
ure 2 where serum TG levels are displayed in two groupsCompared to NoDM, cholesterol concentrations were
significantly higher in PTDM at years one, two and three of patients: NoDM and PTDM before they developed
diabetes. As can be seen, compared to patients with(P  0.01, Kruskall-Wallis). In contrast, cholesterol val-
ues were not significantly different in PTDM and in DM. NoDM, serum TG levels were significantly higher, at
years 1 through 4, in PTDM. After the fourth year, theSerum TG levels (Fig. 1B) were significantly higher in
PTDM than in NoDM throughout the post-transplant numbers of patients in the PTDM group was small (N 
50) and thus this analysis was not done on later years.period (P  0.0001 on years 0 to 4; P  0.01 on years 5
and 6, Kruskall-Wallis). Serum TG in patients with DM Because hypertriglyceridemia preceded the develop-
ment of PTDM, we next examined whether serum TGwere generally lower than those of PTDM and higher
than those in NoDM. These differences in lipid levels levels correlated with the development of PTDM. The
results of a multivariate analysis, including other vari-were not caused by differences in the frequency of use
of lipid lowering agents. In fact, these drugs were used ables shown previously to correlate with the develop-
ment of PTDM [8] are shown in Table 2. As can be seen,significantly more commonly in patients with PTDM
(53% of patients) than in DM (31%) or in NoDM (28%) elevated serum TG levels correlate significantly with a
higher incidence of PTDM and that correlation was inde-(P  0.001 by Chi square).
In patients with PTDM, hypertriglyceridemia pre- pendent of other variables, including increasing age; in-
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Fig. 2. Serum TG levels in NoDM () and PTDM () patients before
they became diabetic. Data are mean  SEM. Values represent means
and standard errors of the mean. By Wilcoxon: year 1, P  0.015; years
2 and 3, P  0.0001; year 4, P  0.001.
Table 2. Correlates of the development of PTDM
(Cox multivariate analysis)
Parameter RRa P
Age years 1.33 0.0001
Race 1.45 0.01
Weightb kg 1.09 0.01
Year of transplantc 1.83 0.0001
TG mg/dL 1.01 0.001
a RR  relative risk that was calculated for every 10 years of age, or every
10 kg of weight or every 10 mg/dL increase in serum TG levels
b Weight was included in this analysis, rather than the BMI, because the dataset
is more complete for this parameter than for BMI values
c Patients in this study were transplanted between 1983 and 1998; the incidence
of PTDM has increased significantly in recent years, particularly since 1995 [8]
creasing weight; African American race; and more recent
transplant year. Regarding the latter variable, we showed
previously that, compared to patients transplanted prior
to 1995, the incidence of PTDM after that year increased
significantly [8]. The correlation between serum TG
Fig. 3. Changes in blood pressure (BP) levels during the first six yearslevels and PTDM was such that 22% of the transplant
after kidney transplantation. (A) Systolic BP, (B) diastolic BP, and (C )recipients with serum TG levels 250 mg/dL developed
pulse pressure in the three groups of patients, NoDM ( ), DM
PTDM compared to 28% in patients TG levels between (. . .) and PTDM ( ). Data are mean  SEM.
250 and 600 mg/dL and 36% of the patients with TG 
600 mg/dL (P  0.02 by 2 analysis).
Blood pressure levels 3B displays the evolution of the diastolic BP in the three
groups of patients. This parameter did not differ signifi-Figure 3 displays the evolution of average yearly BP
cantly between the NoDM and the PTDM groups. How-values throughout the post-transplant. As can be seen
ever, it is notable that patients in the DM group hadin Figure 3A, the systolic BP declined sharply during the
significantly lower diastolic BP than the other two groupsfirst year post-transplant in all three groups of patients,
of patients, except on years 5 and 6 post-transplant (Pand thereafter it remained relatively unchanged. The
0.0001, ANOVA). Finally, Figure 3C displays the evolu-systolic BP was not significantly different in PTDM and
tion of the pulse pressure. Compared to NoDM, pulseDM. However, these two groups of patients had higher
pressure was significantly higher in DM and in PTDMsystolic BP than NoDM at all time points (P  0.0001
by ANOVA except years 4 and 5, P  0.002). Figure at all time points (P  0.0001, ANOVA). A comparison
Cosio et al: Patient survival and post-transplant diabetes1444
between the pulse pressure values in patients in the DM
and PTDM groups revealed the following findings: The
pulse pressure was significantly lower in PTDM than in
DM at years 0 (P 0.0001) and two (P 0.01). However,
after year two the pulse pressure rose progressively in
patients with PTDM and it became not significantly dif-
ferent than the pulse pressure of patients with DM.
The BP changes observed in patients with PTDM pre-
ceded the development of diabetes. Thus, at one year
post-transplant the systolic BP was significantly higher
in patients who later developed PTDM than in NoDM
(143  13 vs. 139  13 mm Hg, P  0.002) and that
difference persisted at two years (137  14 vs. 133  14,
P  0.006). Significant differences were also observed
on the pulse pressure in years one and two post-trans-
plant (data not shown).
Patient survival
During the follow up period, 16% of NoDM patients
died compared to 31% of DM (P  0.0001 by 2) and
22% of PTDM (P 0.01). The cause of death was known
in approximately 50% of the patients in each group.
Compared to NoDM, patients with DM had a signifi-
cantly higher percent of cardiovascular deaths (49 vs.
69%, P  0.02). However, the number of cardiovascular
deaths was not significantly different in NoDM (49%)
and PTDM (54%). The degree of glucose control, mea-
sured as the average HbA1c during the follow-up period,
did not correlate with mortality in either DM or PTDM
patients (data not shown).
Figure 4 displays Kaplan-Meier patient survival plots
in the three groups of patients. The first analysis plotted
Fig. 4. Kaplan-Meier patient survival in the three study groups: NoDMpatient survival from the date of the transplant (Fig. 4A).
(thin line), DM (thick line) and PTDM (dashed line). (A) Survival wasAs can be seen, survival was significantly worse in DM
calculated from the day of transplantation in all three groups of patients.
than in either NoDM or PTDM (log rank P  0.0001 (B) Survival for PTDM was calculated from the time of development
of diabetes and for the other two groups from the day of transplantation.both). The survival plots for patients with PTDM and
NoDM overlapped for approximately 96 months and
thereafter those plots diverged such that, overall, the
survival of PTDM was significantly lower than that of
elevated total serum cholesterol; elevated triglycerides;NoDM (P 0.04 by log rank). A second analysis plotted
and elevated systolic BP during the follow-up period.survival in patients with PTDM from the time of develop-
In addition, there were significant correlations betweenment of diabetes, and compared with the survival in DM
reduced patient survival and lower diastolic BP (RR and NoDM calculated from the transplant day (Fig. 4B).
0.979, P  0.002) and/or higher pulse pressure (RR As can be seen, the survival plots for DM and PTDM
1.029, P 0.0001). Other variables that did not correlateare superimposable and significantly different from the
significantly with patient survival included: recipientsurvival of NoDM (P  0.0001 by log rank).
race; donor age, race or gender; number of acute rejec-Table 3 displays the variables that, by Cox analysis,
tion episodes; graft function at six months post-trans-correlate significantly with patient survival in this popu-
plant; and histocompatibility parameters.lation. It should be noted that in these analyses PTDM
In a multivariate analysis, including only those patientswas analyzed as a time dependent variable. By univariate
who were not diabetic prior to the transplant (Table 3),analysis the variables that correlated with reduced pa-
PTDM was a significant correlate of reduced patienttient survival included: older age; male recipient; remote
survival independently of other variables, including re-rather than more recent transplant year; reduced serum
cipient age and gender, and serum albumin. The trans-albumin during the first year post-transplant; DM pre-
transplant; the development of PTDM; heavier recipient; plant year was not added to this model because we found
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Table 3. Covariates of patient survival (Cox regression analysis)
Variable Number of observationsa Univariable Multivariablec
Age 1811 1.0 (1.03–1.05); P  0.0001b 1.07 (1.05–1.1); P  0.0001
Sex 1811 1.48 (1.16–1.89); P  0.0001 NS
Transplant year 1811 0.96 (0.92–0.99); P  0.01 —g
Serum albumind 1032 0.21 (0.14–0.32); P  0.0001 0.23 (0.14–0.38); P  0.0001
DM pre-transplant 1811 2.2 (1.84–2.76); P  0.0001 Not included
PTDMe 1811 1.80 (1.25–2.41); P  0.001 1.88 (1.07–3.30); P  0.02
Weight 1771 1.007 (1.003–1.01); P  0.007 NS
Total cholesterol 1183 1.003 (1–1.005); P  0.04 NSf
Triglycerides 1159 1.001 (1–1.001); P  0.01 NSf
Systolic BP 1755 1.017 (1.01–1.025); P  0.02 NS
a The number of observations in the first column refer to the univariate analysis only
b Values represent hazard ratio, 95% confidence interval, and P value
c Patients with DM before the transplant were excluded from the multivariate model
d Average values for serum albumin concentration between 6 and 18 months post-transplant
e PTDM was analyzed as a time dependent variable
f Cholesterol and triglycerides were analyzed separately in two different multivariate models
g Transplant year was not included in the multivariable model because we found collinearity between this value and PTDM
a significant co-linearity between this parameter and rarely mentioned as a reason for avoiding the use of
this drug in patients at high risk for PTDM, particularlyPTDM.
African Americans. Perhaps this inconsistency in ap-
proach reflects an incomplete appreciation of the poten-
DISCUSSION tially devastating consequences of PTDM for transplant
The results of this study are consistent with the inter- recipients.
pretation that PTDM is the final manifestation of a com- In addition to elevated TG levels, patients with PTDM
plex metabolic profile that is thought to be the conse- had an unfavorable cardiovascular risk profile that in-
quence of resistance to the actions of insulin [12]. This cluded obesity, elevated total serum cholesterol, elevated
syndrome has received several names including syn- systolic blood pressure, and elevated pulse pressure. Of
drome X, insulin resistance syndrome, and dyslipidemia interest, these parameters did not differ significantly be-
syndrome. Understanding PTDM as a late manifestation tween patients with PTDM and patients with DM prior
of the insulin resistance syndrome provides a reasonable to the transplant, which is striking because DM is statisti-
explanation for the observation made in our current cally the strongest predictor of patient survival after re-
study that, in transplant recipients, the metabolic (dyslip- nal transplantation (for example, [6]). Perhaps this lack
idemia) and hemodynamic (hypertension and widened of difference in cardiovascular risk profile explains the
pulse pressure) abnormalities associated with PTDM pre- observation made here that, calculated from the time of
cede the development of hyperglycemia. development of PTDM, the survival of PTDM and DM
In previous studies we discussed the variables that patients do not differ significantly. Furthermore, the haz-
correlate with the development of PTDM [8]. Those ard ratio for DM and PTDM were quite similar (2.1 and
variables include increasing age, increasing weight, Afri- 1.88, respectively).
can American race, and a transplant done in recent years. Among the cardiovascular risk factors considered in
To that list we now add another independent variable, our current study, it was of particular interest to observe
the presence of elevated serum TG levels, which corre- the evolution of the pulse pressure in patients with DM
late with the subsequent development of hyperglycemia, or PTDM. Pulse pressure was significantly higher during
that is, PTDM. It is hoped that the recognition of factors the first years post-transplant in DM than in PTDM,
that predispose to PTDM will encourage the use of post- because the diastolic BP was significantly lower in pa-
transplant management strategies that could minimize tients with DM. This observation is of interest because,
the risk of PTDM. For example, the literature empha- as shown here and also in previous studies [21, 22], low
sizes the diabetogenic effects of chronic corticosteroid diastolic BP, particularly in association with high systolic
use and the more potent diabetogenic effects of FK506, BP, correlates with an increased cardiovascular risk.
compared to cyclosporine, particularly in African Ameri- With increasing time post-transplant, the pulse pressure
cans [18, 19]. Indeed, the diabetogenic effect of steroids rose in patients with PTDM until it reached values that
is one of the principal reasons for the current empha- were not significantly different from values found in pa-
sis on the application of steroid withdrawal immuno- tients with DM. Pulse pressure is now recognized as a
suppressive protocols following transplantation [20]. In statistically strong correlate of CV risk [23, 24].
Because the measured CV risk factors were abnormalcontrast, the potent diabetogenic effect of FK506 is
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diovascular disease in chronic renal disease. Am J Kidney Dis 32in patients with PTDM before the development of hyper-
(Suppl 3):S112–S119, 1998
glycemia it is perhaps not surprising that PTDM corre- 4. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic
of cardiovascular disease in chronic renal disease: What do welates significantly with reduced patient survival, despite
know? What do we need to learn? Where do we go from here?the relatively short duration of diabetes. Indeed, these National Kidney Foundation Task Force on Cardiovascular Dis-
observations also raise the following disturbing ques- ease. Am J Kidney Dis 32:853–906, 1998
5. Kasiske BL, Chakkera HA, Roel J: Explained and unexplainedtions: If diabetes is only the final, late manifestation of
ischemic heart disease risk after renal transplantation. J Am Socthe insulin resistance syndrome, what is the actual preva- Nephrol 11:1735–1743, 2000
6. Cosio FG, Alamir A, Yim S, et al: Patient survival after renallence of this syndrome in recipients of kidney trans-
transplantation: I. The impact of dialysis pre-transplant. Kidneyplants? Furthermore, what is the contribution of the
Int 53:767–772, 1998
insulin resistance syndrome, with its associated complex 7. Cosio FG, Falkenhain ME, Pesavento TE, et al: Patient survival
after renal transplantation: II. The impact of smoking. Clin Trans-metabolic and hemodynamic abnormalities, to the high
plant 13:336–341, 1999cardiovascular risk of these patients? 8. Cosio FG, Pesavento TE, Osei K, et al: Post-transplant diabetes
mellitus: Increasing incidence in renal allograft recipients trans-In this study we did not analyze the morbidity associ-
planted in recent years. Kidney Int 59:732–737, 2001ated with PTDM nor the potential impact of PTMD on
9. Weir M, Fink J: Risk for posttransplant diabetes mellitus with
graft survival. The latter effect is controversial and while current immunosuppressive medications. Am J Kidney Dis 34:1–
13, 1999some publications showed that PTDM is associated with
10. Benowitz NL: Drug therapy. Pharmacologic aspects of cigarettereduced death censored kidney graft survival, others did smoking and nicotine addition. N Engl J Med 319:1318–1330, 1988
not [reviewed in 9, 16]. Analyses of data from patients 11. Reaven GM, Lithell H, Landsberg L: Hypertension and associ-
ated metabolic abnormalities—The role of insulin resistance andtransplanted in our institution showed that PTDM is
the sympathoadrenal system. N Engl J Med 334:374–381, 1996
not associated with significantly reduced renal allograft 12. Reaven GM: Pathophysiology of insulin resistance in human dis-
ease. Physiol Rev 75:473–486, 1995survival (data not shown). However, clearly the develop-
13. Meigs JB, Mittleman MA, Nathan DM, et al: Hyperinsulinemia,ment of diabetes, with time, will have deleterious effects hyperglycemia, and impaired hemostasis: The Framingham Off-
on the transplanted organ. For example, anecdotally we spring Study. JAMA 283:221–228, 2000
14. Alvestrand A: Carbohydrate and insulin metabolism in renalhave observed patients with PTDM who develop classic
failure. Kidney Int 52(Suppl 62):S48–S52, 1997
diabetic glomerulosclerosis in the allograft after more 15. Fliser D, Pacini G, Engelleiter R, et al: Insulin resistance and
hyperinsulinemia are already present in patients with incipientthan five years post-transplant. As the survival of renal
renal disease. Kidney Int 53:1343–1347, 1998allografts and that of renal allograft recipients continues 16. Jindal RM, Hjelmesaeth J: Impact and management of posttrans-
to improve [1, 2], it is inevitable that the magnitude of plant diabetes mellitus. Transplantation 70(Suppl):SS58–SS63, 2000
17. Bumgardner GL, Wilson GA, Tso PL, et al: Impact of serum lipidsthe negative impact of PTDM on graft and patient sur-
on long-term graft and patient survival after renal transplantation.
vival will increase. For all of the reasons proposed above, Transplantation 60:1418–1421, 1995
18. Johnson C, Ahsan N, Gonwa T, et al: Randomized trial of tacro-we believe that the diagnosis, prevention, pathogenesis,
limus (Prograf) in combination with azathioprine or mychophe-and treatment of insulin resistance after transplantation nolate mofetil versus cyclosporine (Neoral) with mycophenolate
should be a major focus for future research. mofetil after cadaveric kidney transplantation. Transplantation 69:
834–841, 2000
19. Neylan JF: Racial differences in renal transplantation after immu-
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